Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (7): 689-692.doi: 10.35541/cjd.20201086

• Reviews • Previous Articles     Next Articles

Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis

Jiang Xiaoyan1, Gao Min2, Zhang Xiaoyan3, Liu Ningyuan1   

  1. 1China-Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, China; 2China-Japan Friendship Clinical Medical College, Peking University Health Science Center, Beijing 100029, China; 3Department of Dermatology and Venereology, China-Japan Friendship Hospital, Beijing 100029, China
  • Received:2020-11-12 Revised:2022-03-07 Online:2023-07-15 Published:2023-07-04
  • Contact: Zhang Xiaoyan

Abstract: 【Abstract】 Pustular psoriasis is a serious life-threatening disease, and patients usually show poor response to traditional treatments. In recent years, interleukin-17 and interleukin-23 inhibitors have shown favorable efficacy in the treatment of psoriasis. This review summarizes the latest progress in interleukin-17 and interleukin-23 inhibitors for the treatment of pustular psoriasis.

Key words: Psoriasis, Interleukin-17, Interleukin-23, Generalized pustular psoriasis, Acrodermatitis continua of Hallopeau, Palmoplantar pustulosis